Changes in cystic fibrosis transmembrane conductance regulator protein expression prior to and during elexacaftor-tezacaftor-ivacaftor therapy

Background: Defects in expression, maturation or function of the epithelial membrane glycoprotein CFTR are causative for the progressive disease cystic fibrosis. Recently, molecular therapeutics that improve CFTR maturation and functional defects have been approved. We aimed to verify whether we cou...

Descripción completa

Detalles Bibliográficos
Autores principales: Stanke, Frauke, Pallenberg, Sophia T., Tamm, Stephanie, Hedtfeld, Silke, Eichhorn, Ella M., Minso, Rebecca, Hansen, Gesine, Welte, Tobias, Sauer-Heilborn, Annette, Ringshausen, Felix C., Junge, Sibylle, Tümmler, Burkhard, Dittrich, Anna-Maria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9911415/
https://www.ncbi.nlm.nih.gov/pubmed/36778025
http://dx.doi.org/10.3389/fphar.2023.1114584

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9911415/
https://www.ncbi.nlm.nih.gov/pubmed/36778025
http://dx.doi.org/10.3389/fphar.2023.1114584

Ejemplares similares